Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster; Postherpetic neuralgia; Varicella zoster virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZOE-70
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Oct 2017 According to an Agenus media release, based on the pooled data from this and other trial ( see profile 57959), the US FDA granted marketing authorization to SHINGRIX for prevention of herpes zoster (shingles) in adults aged 50 years and older.
    • 13 Oct 2017 SHINGRIX has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older, as reported in a GlaxoSmithKline media release.
    • 08 Oct 2017 Results (n=29,305) of a pooled safety analysis from NCT01165177 and NCT01165229 studies, presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top